, Volume 44, Issue 1, pp 40–46

Osteoporosis in men: recent progress



As osteoporosis in men has been recognized as an important clinical problem, new information is being accumulated on its scope, pathophysiology, evaluation, and treatment. Fracture risk calculators, such as FRAX, identify a large proportion of the older male population to be at heightened risk for fracture. The classification of osteoporosis into primary and secondary forms, while still useful, is affected by the fact that many men have multiple contributing factors to their fracture risk. The role of sex steroids is being better defined as other risk factors for fracture are delineated. As longevity continues to increase in men and until osteoporotic fracture is truly recognized as a potentially fatal disorder, many men will be undiagnosed and untreated. Two recent studies provide more evidence that treatments which decrease fracture risk in women do the same in men. With the publication of guidelines and increasing strength of evidence for treatment efficacy, it is hoped that more men will be evaluated and treated for this often neglected disorder.


Osteoporosis Fracture Men Dual energy x-ray absorptiometry Bisphosphonates 


  1. 1.
    R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, A.N. Toteston, Incidence and economic burden of osteoporosis-related fracture and subsequent fracture in men and women. JAMA 22, 365–475 (2007)Google Scholar
  2. 2.
    S. Khosla, L.J. Melton III, E.J. Atkinson, W.M. O’Falon, Relationship of serum sex steroids to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86, 3555–3561 (2001)PubMedCrossRefGoogle Scholar
  3. 3.
    T.P. van Staa, E.M. Dennison, H.G. Leufkens, C. Cooper, Epidemiology of fractures in England and Wales. Bone 29, 517–522 (2001)PubMedCrossRefGoogle Scholar
  4. 4.
    R.B. Hopkins, E. Pullenayegum, R. Goeree, J.D. Adachi, A. Papaioannou, W.E. Leslie, J.E. Tarride, L. Thabane, Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos. Int. 23, 921–927 (2012)PubMedCrossRefGoogle Scholar
  5. 5.
    A.C. Feldstein, G. Nichols, E. Orwoll, P.J. Elmer, D.H. Smith, M. Herson, M. Aickin, The near absence of osteoporosis treatment in older men with fractures. Osteoporos. Int. 16, 953–962 (2005)PubMedCrossRefGoogle Scholar
  6. 6.
    J.R. Center, D. Bliuc, T.V. Nguyen, J.A. Eisman, Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 24, 387–394 (2007)CrossRefGoogle Scholar
  7. 7.
    J.E. Block, H. Stubbs, Hip fracture-associated mortality reconsidered. Calcif. Tissue Int. 61, 84 (1997)PubMedCrossRefGoogle Scholar
  8. 8.
    T.P. van Staa, H.G. Leufkens, L. Abenhaim, B. Zhang, C. Cooper, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxf.) 39, 1383–1389 (2000)CrossRefGoogle Scholar
  9. 9.
    R.A. Adler, M.C. Hochberg, Glucocorticoid-induced osteoporosis in men. J. Endocrinol. Investig. 34, 481–484 (2011)Google Scholar
  10. 10.
    G.L. Lu-Yao, P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, R.S. DiPaola, S.L. Yao, Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300, 173–181 (2008)PubMedCrossRefGoogle Scholar
  11. 11.
    V.B. Shahinian, Y.F. Kuo, J.L. Freeman, J.S. Goodwin, Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154–164 (2005)PubMedCrossRefGoogle Scholar
  12. 12.
    B.L. Riggs, L.J. Melton III, Involutional osteoporosis. N. Engl. J. Med. 314, 1676–1686 (1986)PubMedCrossRefGoogle Scholar
  13. 13.
    R.A. Adler, Osteoporosis in men: insights for the clinician. Ther Adv Musculoskelet Dis 3, 191–200 (2011)PubMedCrossRefGoogle Scholar
  14. 14.
    J.A. Kanis, H. Johansson, A. Oden, B. Dawson-Hughes, L.J. Melton III, E.V. McCloskey, The effects of a FRAX revision for the USA. Osteoporos. Int. 21, 35–40 (2010)PubMedCrossRefGoogle Scholar
  15. 15.
    N.D. Nguyen, S.A. Frost, J.R. Center, J.A. Eisman, T.V. Nguyen, Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos. Int. 18, 1109–1117 (2008)CrossRefGoogle Scholar
  16. 16.
    C.S. Ryan, V.I. Petkov, R.A. Adler, Osteoporosis in men: the value of laboratory testing. Osteoporos. Int. 22, 1845–1853 (2011)PubMedCrossRefGoogle Scholar
  17. 17.
    E. Romagnoli, R. Del Fiacco, S. Russo, S. Piemonte, F. Fidanza, F. Colapietro, D. Diacinti, C. Cipriani, S. Minisola, Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J. Rheumatol. 38, 1671–1679 (2011)PubMedCrossRefGoogle Scholar
  18. 18.
    L.E. Ryan, S.W. Ing, Idiopathic hypercalciuria and bone health. Curr. Osteoporos. Rep. 10, 286–295 (2012)PubMedCrossRefGoogle Scholar
  19. 19.
    P. Vestergaard, L. Rejnmark, L. Mosekilde, Fracture risk associated with the use of morphine and opiates. J. Intern. Med. 260, 76–87 (2006)PubMedCrossRefGoogle Scholar
  20. 20.
    S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, M.R. Blackman, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724–731 (2001)PubMedCrossRefGoogle Scholar
  21. 21.
    J.M. Kaufman, A. Vermeulen, The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833–876 (2005)PubMedCrossRefGoogle Scholar
  22. 22.
    G. Sartorius, S. Spasevska, A. Idan, L. Turner, E. Forbes, A. Zamojska, C.A. Allan, L.P. Ly, A.J. Conway, R.I. McLachlan, D.J. Handelsman, Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin. Endocrinol. 77, 755–763 (2012)CrossRefGoogle Scholar
  23. 23.
    P. Dandona, S. Dhindsa, Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J. Clin. Endocrinol. Metab. 96, 2643–2651 (2011)PubMedCrossRefGoogle Scholar
  24. 24.
    K.M. Wiren, A. Chapman Evans, X.W. Zhang, Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J. Endocrinol. 175, 683–694 (2002)PubMedCrossRefGoogle Scholar
  25. 25.
    H. Lee, J.S. Finkelstein, M. Miller, S.J. Comeaux, R.I. Cohen, B.Z. Leder, Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J. Clin. Endocrinol. Metab. 91, 1069–1075 (2006)PubMedCrossRefGoogle Scholar
  26. 26.
    D. Merlotti, L. Gennari, K. Stolakis, R. Nuti, Aromatase activity and bone loss in men. J. Osteoporos. 2011, 230671 (2011). doi:10.4061/2011/230671 PubMedGoogle Scholar
  27. 27.
    C.M. Nielson, L.M. Marshall, A.L. Adams, E.S. LeBlanc, P.M. Cawthon, K. Ensrud, E. Barrett-Connor, E.S. Orwoll, Osteoporotic Fractures in Men Study Research Group. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J. Bone Miner. Res. 26, 496–502 (2011)PubMedCrossRefGoogle Scholar
  28. 28.
    L.A. Fitzpatrick, Secondary causes of osteoporosis. Mayo Clin. Proc. 77, 453–468 (2002)PubMedGoogle Scholar
  29. 29.
    R.A. Adler, Laboratory testing for secondary osteoporosis evaluation. Clin. Biochem. 45, 894–900 (2012)PubMedCrossRefGoogle Scholar
  30. 30.
    G. Mazziotti, T. Porcelli, M. Mormando, E. De Menis, A. Bianchi, C. Mejia, T. Mancini, L. De Marinis, A. Giiustina, Vertebral fractures in males with prolactinoma. Endocrine 39, 288–293 (2011)PubMedCrossRefGoogle Scholar
  31. 31.
    C. Torti, G. Mazziotti, P.A. Soldini, E. Foca, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)PubMedCrossRefGoogle Scholar
  32. 32.
    T.T. Dam, S. Harrison, H.A. Fink, J. Ramsdell, E. Barrett-Connor, Osteoporotic Fractures in Men (MrOS) Research Group, Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos. Int. 21, 1341–1349 (2010)PubMedCrossRefGoogle Scholar
  33. 33.
    G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)PubMedCrossRefGoogle Scholar
  34. 34.
    C.E. Lewis, S.K. Ewing, B.C. Taylor, J.M. Shikany, H.A. Fink, K.E. Ensrud, E. Barrett-Connor, S.R. Cummings, E.S. Orwoll, Osteoporotic Fractures in Men (MrOs) Study Research Group, Predictors of non-spine fracture in elderly men: the MrOS Study. J. Bone Miner. Res. 22, 211–219 (2007)PubMedCrossRefGoogle Scholar
  35. 35.
    J.A. Cauley, G. El Hajj Fuleihan, A. Arabi, S. Fujiwara, S. Ragi-Eis, A. Calderon, S.B. Chionh, Z. Chen, J.R. Curtis, M.E. Danielson, D.A. Hanley, H. Kroger, A.W. Kung, O. Lesnyak, J. Nieves, W. Pluskiewicz, R. El Rassi, S. Silverman, A.M. Schott, R. Rizzoli, M. Luckey, FRAX Position Conference Members, Official positions for FRAX clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis on FRAX. J. Clin. Densitom. 14, 240–262 (2011)PubMedCrossRefGoogle Scholar
  36. 36.
    J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism. Arq. Bras. Endocrinol. Metab. 54, 106–109 (2010)CrossRefGoogle Scholar
  37. 37.
    N. Binkley, R.A. Adler, Dual-energy X-ray absorptiometry (DXA) in men, in Osteoporosis in Men, 2nd edn., ed. by E.S. Orwoll, J.P. Bilezikian, D. Vanderschueren (Academic Press, New York, 2010), pp. 525–540CrossRefGoogle Scholar
  38. 38.
    T. Isaksen, C.S. Nielsen, S.E. Christensen, P.H. Nissen, L. Heickendorff, L. Mosekilde, Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif. Tissue Int. 89, 285–294 (2011)PubMedCrossRefGoogle Scholar
  39. 39.
    D.K. Dhanwal, N. Kochupillai, N. Gupta, C. Cooper, E.M. Dennison, Hypovitaminosis D and bone mineral metabolism and bone density in hyperthyroidism. J. Clin. Densitom. 13, 462–466 (2010)PubMedCrossRefGoogle Scholar
  40. 40.
    D. Mittan, S. Lee, E. Miller, R.C. Perez, J.W. Basler, J.M. Bruder, Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 87, 3656–3661 (2002)PubMedCrossRefGoogle Scholar
  41. 41.
    J.A. Kanis, L.J. Melton III, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137–1141 (1994)PubMedCrossRefGoogle Scholar
  42. 42.
    J.A. Kanis, G. Bianchi, J.P. Bilezikian, J.M. Kaufman, S. Khosla, E. Orwoll, E. Seeman, Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22, 2789–2798 (2011)PubMedCrossRefGoogle Scholar
  43. 43.
    P.L. Selby, P.L. Davies, J.E. Adams, Do men and women fracture bones at similar bone densities? Osteoporos. Int. 11, 153–157 (2000)PubMedCrossRefGoogle Scholar
  44. 44.
    R.A. Adler, Osteoporosis in men: what has changed? Curr. Osteoporos. Rep. 9, 31–35 (2011)PubMedCrossRefGoogle Scholar
  45. 45.
    M.G. Donaldson, P.M. Cawthon, L.Y. Lui, J.T. Schousboe, K.E. Ensrud, B.C. Taylor, J.A. Cauley, T.A. Hillier, T.T. Dam, J.R. Curtis, D.M. Black, D.C. Bauer, E.S. Orwoll, S.R. Cummings, Osteoporotic Fractures in Men (MrOS) Study Group, Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation Guidelines. J. Bone Miner. Res. 25, 1506–1511 (2010)PubMedCrossRefGoogle Scholar
  46. 46.
    G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRefGoogle Scholar
  47. 47.
    E.S. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343, 604–610 (2000)PubMedCrossRefGoogle Scholar
  48. 48.
    L.H. Klotz, I.Y. McNeill, M. Kebabdjian, L. Zhang, J. Chin, Canadian Urology Research Consortium, A phase 3, double-blind, randomized, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study. Eur. Urol. doi:10.1016/j.eururu.2012.09.007
  49. 49.
    S. Boonen, E.S. Orwoll, D. Wenderoth, K.J. Stoner, R. Eusebio, P.D. Delmas, Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24, 719–725 (2009)PubMedCrossRefGoogle Scholar
  50. 50.
    P. Taxel, R. Dowsett, L. Richter, P. Fall, A. Klepinger, P. Albertsen, Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int. 106, 1473–1476 (2010)PubMedCrossRefGoogle Scholar
  51. 51.
    E.S. Orwoll, N.C. Binkley, E.M. Lewiecki, U. Gruntmanis, M.A. Fries, G. Dasic, Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46, 970–976 (2010)PubMedCrossRefGoogle Scholar
  52. 52.
    E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, D. Kendler, C. Bucci-Rechtweg, A. Readie, P. Messenbrink, R.S. Weinstein, Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 25, 2239–2250 (2010)PubMedCrossRefGoogle Scholar
  53. 53.
    S. Boonen, J.Y. Reginster, J.M. Kaufman, K. Lippuner, J. Zanchetta, B. Langdahl, R. Rizzoli, S. Lipschitz, H.P. Dimai, R. Witvrouw, E. Eriksen, K. Brixen, L. Russo, F. Claessens, P. Papanastasiou, O. Antunez, G. Su, C. Bucci-Rechtweg, J. Hruska, E. Incera, D. Vanderschueren, E. Orwoll, Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med. 367, 1714–1723 (2012)PubMedCrossRefGoogle Scholar
  54. 54.
    K. Sinningen, E. Tsourdi, M. Rauner, T.D. Rachner, C. Hamann, L.C. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42, 52–62 (2012)PubMedCrossRefGoogle Scholar
  55. 55.
    E. Orwoll, C.S. Teglbjaerg, B.L. Langdahl, R. Chapurlat, E. Czerwinski, D.L. Kendler, J.Y. Reginster, A. Kivitz, E.M. Lewiecki, P.D. Miller, M.A. Bolognese, M.R. McClung, H.G. Bone, P. Ljimggrem, B. Abrahamsne, U. Gruntmanis, Y.C. Yang, R.B. Wagman, S. Siddhanti, A. Grauer, J.W. Hall, S. Boonen, A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J. Clin. Endocrinol. Metab. 97, 3161–3169 (2012)PubMedCrossRefGoogle Scholar
  56. 56.
    M.R. Smith, B. Egerdie, N.H. Toriz, R. Feldman, T.L. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, B.Z. Leder, C. Goessl, Denosumab HALT Prostate Cancer Study Group, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009)PubMedCrossRefGoogle Scholar
  57. 57.
    N.E. Cusano, A.G. Costa, B.C. Silva, J.P. Bilezikian, Therapy of osteoporosis in men with teriparatide. J. Osteoporos. 2011, 463675 (2011). doi:10.4061/2011/463675
  58. 58.
    J.M. Kaufman, E. Orwoll, S. Goemaere, J. San Martin, A. Hossain, G.P. Dalsky, R. Linsday, B.H. Mitlak, Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 16, 510–516 (2005)PubMedCrossRefGoogle Scholar
  59. 59.
    J.D. Ringe, A. Dorst, P. Farahmand, Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 60, 267–272 (2010)PubMedGoogle Scholar
  60. 60.
    H.M. Behre, S. Kliesch, E. Leifke, T.M. Link, E. Nieschlag, Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82, 2386–2390 (1997)Google Scholar
  61. 61.
    J.K. Amory, N.B. Watts, K.A. Easley, P.R. Sutton, B.D. Anawalt, A.M. Matsumoto, W.J. Bremer, J.L. Tenover, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503–510 (2004)PubMedCrossRefGoogle Scholar
  62. 62.
    P.J. Snyder, H. Peachey, P. Hannoush, J.A. Berlin, L. Loh, J.H. Holmes, A. Dlewati, J. Staley, J. Santanna, S.C. Kapoor, M.F. Attie, J.G. Haddad Jr., B.L. Strom, Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84, 1966–1972 (1999)PubMedCrossRefGoogle Scholar
  63. 63.
    N.B. Watts, R.A. Adler, J.P. Bilezikian, M.T. Drake, R. Eastell, E.S. Orwoll, J.S. Finkelstein, Osteoporosis in men: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 97, 1802–1822 (2012)PubMedCrossRefGoogle Scholar
  64. 64.
    J. Compston, Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos. Int. 22, 2951–2961 (2011)PubMedCrossRefGoogle Scholar
  65. 65.
    S.V. Reddy, S.K. Gupta, Atypical femoral shaft fractures in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singap. Med. J. 53, e52–e54 (2012)Google Scholar
  66. 66.
    N.B. Watts, D.L. Diab, Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 95, 1555–1565 (2010)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2013

Authors and Affiliations

  1. 1.Endocrinology and Metabolism (111P)McGuire Veterans Affairs Medical Center, Virginia Commonwealth University School of MedicineRichmondUSA

Personalised recommendations